The company
iShares Biotechnology ETF
IBB · Nasdaq · fund
IBB stood above a rising 150-day average in 49 of the last 52 weekly readings, including each of the last 19 weeks. It is 12.8% above that average now.
Statistics
- Rotation
- not in the set
- Weeks in an uptrend
- 19 in a row
- Officials’ trades on record
- 6
In the rotation
Each square a week: lit when it closed above a rising 150-day average. 49 of 52 weeks.
Money in and out
1 Nov 2024 – 1 Oct 2026
Open-market buys above the line and sales below, in dollars. Not yet read: institutions.
Congress and officials
6 disclosed lines: House 6, Senate 0, executive 0; 5 people.
| Who | Did | Amount | Traded |
|---|---|---|---|
| David P. Joyce House: U.S. House ClerkOH14 | sold | $1k–$15k | 23 Feb 2017filed 8 May 2019 |
| David P. Joyce House: U.S. House ClerkOH14 | sold | $1k–$15k | 17 Feb 2017filed 26 Jul 2017 |
| Carlos Curbelo House: U.S. House ClerkFL26 | soldspouse | $1k–$15k | 30 Dec 2016filed 10 Jan 2017 |
| Richard L. Hanna House: U.S. House ClerkNY22 | sold | $1k–$15k | 28 Dec 2016filed 18 Jan 2017 |
| J. French Hill House: U.S. House ClerkAR02 | bought | $15k–$50k | 31 May 2016filed 12 Jul 2016 |
| Carlos Curbelo House: U.S. House ClerkFL26 | bought | $1k–$15k | 25 May 2016filed 16 Jun 2016 |
Insiders
Buy orders, 12 months0
Sale orders, 12 months0
Buyers · sellers0
No open-market buy or sale by its insiders on record.
Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.
Institutions
Still reading this part; it fills in a moment.
News
Better Buy: Fidelity Health Care ETF (FHLC) or iShares Biotechnology ETF (IBB)?fool.com · 13 Oct 2026Better Buy: Fidelity Health Care ETF (FHLC) or iShares Biotechnology ETF (IBB)?fool.com · 13 Oct 2026iShares Biotechnology ETF (IBB) Stock News & Articles247wallst.com · 5 Oct 20265 Undervalued Oncology Stocks Wall Street Is Overlooking (NASDAQ:IBB)seekingalpha.com · 18 Sep 2026
Everyone who traded it
Same industry
No other stock in its industry this week.
Government contracts
No federal award is tied to it.
From its SEC filings
No ratio computed from its SEC filings yet.
Analyst forecasts
No analyst forecasts yet.